Rusan Pharma, a leading player in pain management, movement disorders, and addiction treatment, has achieved a major global regulatory milestone. The company successfully secured Good Manufacturing Practice (GMP) approvals from Pharmaceuticals and Medical Devices Agency (PMDA), Japan. This achievement reinforces Rusan Pharma’s commitment to world-class quality, regulatory compliance, and manufacturing excellence.
Approval Across Key Manufacturing Facilities
Importantly, Rusan Pharma obtained GMP approval for two of its critical facilities. Its Active Pharmaceutical Ingredient (API) manufacturing unit in Ankleshwar, Gujarat, and its Small Volume Parenterals (Ampoules) Finished Dosage Formulation (FDF) facility in Dehradun, Uttarakhand, both met the stringent standards set by the Japanese regulator. Notably, PMDA is widely recognized as one of the most rigorous regulatory authorities globally, making this approval particularly significant.
Leadership Perspective on the Achievement
Commenting on the milestone, Kunal Saxena, Managing Director of Rusan Pharma, expressed pride in the accomplishment. He stated that receiving GMP approval from Japan’s PMDA for both API and FDF facilities places Rusan among a select group of companies worldwide. Furthermore, he emphasized that this recognition strengthens the company’s position as a trusted partner in pharmaceutical development, manufacturing, and licensing. He also highlighted that the achievement reflects the dedication of Rusan’s teams, the robustness of its systems, and its unwavering focus on delivering high-quality products to patients and partners globally.
Strengthening Global Market Presence
As a result of this milestone, Rusan Pharma significantly enhances its ability to serve highly regulated markets such as Japan. Moreover, the approval supports the company’s strategy to expand its portfolio of high-quality pharmaceutical offerings and strengthen its global footprint.
Driving Future Growth and Excellence
Looking ahead, Rusan Pharma continues to invest in upgrading its manufacturing infrastructure, strengthening quality systems, and enhancing regulatory readiness. Consequently, the company aims to solidify its position as a reliable global partner in pharmaceutical manufacturing and healthcare delivery, driven by a long-term vision of excellence and innovation.